熱門資訊> 正文

艾伯维完成对Capstan Therapeutics的收购

2025-08-19 22:26

AbbVie (NYSE:ABBV) has completed its acquisition of clinical-stage biotech Capstan Therapeutics.
The deal, first announced in late June, is worth up to $2.1B.
Captan's lead asset, CPTX2309, is a targeted lipid nanoparticle, anti-CD19 CAR-T therapy for B cell-mediated autoimmune diseases in phase 1.

More on AbbVie

AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition
AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript
4 Reasons To Buy AbbVie
Short bets on S&P 500 Healthcare sector ease in July; Moderna remains most heavily shorted stock
AbbVie to invest $195M to build plant in Illinois

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。